Epstein-Barr virus serology and gastric cancer incidence and survival

J Koshiol; Y-L Qiao; S D Mark; S M Dawsey; C C Abnet; F Kamangar; E T Lennette; Z-W Dong; P R Taylor

doi:10.1038/sj.bjc.6604063

Epstein-Barr virus serology and gastric cancer incidence and survival

Br J Cancer. 2007 Dec 3;97(11):1567-9. doi: 10.1038/sj.bjc.6604063. Epub 2007 Nov 6.

Authors

J Koshiol¹, Y-L Qiao, S D Mark, S M Dawsey, C C Abnet, F Kamangar, E T Lennette, Z-W Dong, P R Taylor

Affiliation

¹ Cancer Prevention Fellowship, Division of Cancer Prevention, National Cancer Institute, 6120 Executive Blvd., MSC 7236, Bethesda, MD, USA. koshiolj@mail.nih.gov

Abstract

Among 185 cases of gastric cancer and 200 controls in Linxian, China, Epstein-Barr virus (EBV) seropositivity was not associated with increased risk of gastric cancer. High EBV nuclear antigen titres were associated with longer survival in cardia cancer cases, possibly due to chance.

MeSH terms

Antibodies, Viral / blood
Antigens, Viral / immunology
Capsid Proteins / immunology
Case-Control Studies
China / epidemiology
Epstein-Barr Virus Infections / blood*
Epstein-Barr Virus Infections / virology
Epstein-Barr Virus Nuclear Antigens / immunology
Female
Herpesvirus 4, Human / immunology*
Humans
Immunoglobulin A / blood
Immunoglobulin G / blood
Incidence
Kaplan-Meier Estimate
Logistic Models
Male
Middle Aged
Odds Ratio
Stomach Neoplasms / epidemiology*

Substances

Antibodies, Viral
Antigens, Viral
Capsid Proteins
Epstein-Barr Virus Nuclear Antigens
Epstein-Barr viral capsid antigen
Immunoglobulin A
Immunoglobulin G